Novartis shares positive late-stage results for Fabhalta in rare kidney disease C3 glomerulopathy
Approximately one to two people per million worldwide are diagnosed with C3G every year
Source: pmlive.com
David Soergel News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from David Soergel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In David Soergel Today - Breaking & Trending Today
Novartis: presented results for kidney disease
Novartis has presented the results of a pre-specified interim analysis of the Phase III ALIGN study of atrasentan, an investigational oral selective endothelin A receptor antagonist, in patients with...
Source: marketscreener.com
Novartis' atrasentan shows to reduce proteinuria in Phase III IgAN trial
Atrasentan’s safety profile in the trial was deemed favourable, aligning with previous data.
Source: yahoo.com
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label...
Source: prnewswire.com
Novartis Pharma AG: Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical meeting2
Source: finanznachrichten.de